![]() |
Volumn 57, Issue 4, 2001, Pages 77-80
|
Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
a b c d e f
d
Parke Davis
*
(United States)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE;
ANTINEOPLASTIC AGENT;
GENISTEIN;
ISOFLAVONE DERIVATIVE;
LEFLUNOMIDE;
PROTEIN FARNESYLTRANSFERASE INHIBITOR;
PROTEIN TYROSINE KINASE INHIBITOR;
PTI G 2535;
PTI G 4660;
UNCLASSIFIED DRUG;
CANCER PREVENTION;
CELL DIFFERENTIATION;
CELL GROWTH;
CHEMOPROPHYLAXIS;
CONFERENCE PAPER;
CYTOLOGY;
DRUG MECHANISM;
ENZYME INHIBITION;
HUMAN;
PRIORITY JOURNAL;
PROSTATE CANCER;
SIGNAL TRANSDUCTION;
ALKYL AND ARYL TRANSFERASES;
ANGIOGENESIS INHIBITORS;
ANTICARCINOGENIC AGENTS;
ENZYME INHIBITORS;
FARNESYLTRANSTRANSFERASE;
GENISTEIN;
HUMANS;
MALE;
PROSTATIC NEOPLASMS;
PROTEIN-TYROSINE KINASES;
RECEPTOR, ERBB-2;
SIGNAL TRANSDUCTION;
|
EID: 0034977872
PISSN: 00904295
EISSN: None
Source Type: Journal
DOI: 10.1016/S0090-4295(00)00946-8 Document Type: Article |
Times cited : (24)
|
References (12)
|